Novo Nordisk A/S

Company Profile

Novo Nordisk A/S had its IPO on 1982-01-04 under the ticker symbol NVO.

The company operates in the Healthcare sector and Biotechnology industry. Novo Nordisk A/S has a staff strength of 59,337 employees.

Stock update

Shares of Novo Nordisk A/S opened at $196.28 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $194.04 - $197.67, and closed at $196.75.

This is a -1.4% slip from the previous day's closing price.

A total volume of 3,575,243 shares were traded at the close of the day’s session.

In the last one week, shares of Novo Nordisk A/S have increased by +3.93%.

Novo Nordisk A/S's Key Ratios

Novo Nordisk A/S has a market cap of $446.46 billion, indicating a price to book ratio of 27.8982 and a price to sales ratio of 1.7848.

In the last 12-months Novo Nordisk A/S’s revenue was $201.33 billion with a gross profit of $148.51 billion and an EBITDA of $92.89 billion. The EBITDA ratio measures Novo Nordisk A/S's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Novo Nordisk A/S’s operating margin was 43.2% while its return on assets stood at 21.76% with a return of equity of 81.54%.

In Q2, Novo Nordisk A/S’s quarterly earnings growth was a positive 47.3% while revenue growth was a positive 31.6%.

Novo Nordisk A/S’s PE and PEG Ratio

Forward PE

31.1526

Trailing PE

46.7307

PEG

2.0301

Its diluted EPS in the last 12-months stands at $4.27 per share while it has a forward price to earnings multiple of 31.1526 and a PEG multiple of 2.0301. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Novo Nordisk A/S’s profitability.

Novo Nordisk A/S stock is trading at a EV to sales ratio of 1.7787 and a EV to EBITDA ratio of 3.7037. Its price to sales ratio in the trailing 12-months stood at 1.7848.

Novo Nordisk A/S stock pays annual dividends of $14.15 per share, indicating a yield of 1.03% and a payout ratio of 5.34%.

Balance sheet and cash flow metrics

Total Assets

$280.75 billion

Total Liabilities

$156.62 billion

Operating Cash Flow

$-15932000000.00

Capital Expenditure

$7.04 billion

Dividend Payout Ratio

5.34%

Novo Nordisk A/S ended 2024 with $280.75 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $280.75 billion while shareholder equity stood at $90.47 billion.

Novo Nordisk A/S ended 2024 with $0 in deferred long-term liabilities, $156.62 billion in other current liabilities, 451000000.00 in common stock, $88.12 billion in retained earnings and $0 in goodwill. Its cash balance stood at $21.57 billion and cash and short-term investments were $36.41 billion. The company’s total short-term debt was $6,289,000,000 while long-term debt stood at $19.42 billion.

Novo Nordisk A/S’s total current assets stands at $137.55 billion while long-term investments were $1.48 billion and short-term investments were $14.83 billion. Its net receivables were $70.52 billion compared to accounts payable of $17.79 billion and inventory worth $28.02 billion.

In 2024, Novo Nordisk A/S's operating cash flow was $-15932000000.00 while its capital expenditure stood at $7.04 billion.

Comparatively, Novo Nordisk A/S paid $0.05 in dividends in 2024.

Other key metrics

Current Trading Price

$196.75

52-Week High

$201.76

52-Week Low

$93.8191

Analyst Target Price

$186.76

Novo Nordisk A/S stock is currently trading at $196.75 per share. It touched a 52-week high of $201.76 and a 52-week low of $201.76. Analysts tracking the stock have a 12-month average target price of $186.76.

Its 50-day moving average was $173.09 and 200-day moving average was $153.69 The short ratio stood at 1.09 indicating a short percent outstanding of 0%.

Around 0.7% of the company’s stock are held by insiders while 822.3% are held by institutions.